A4CELL Celebrates a Remarkable Year with €3 MillionInvestment to Transform Living Single Cell Analysis
This momentousinvestment will serve as the catalyst for revolutionizing the landscape of living single cellanalysis.
We will be able to pioneer advancements in the analysis of livingsingle cells with the €3 million investment secured through acollaborative effort and unwavering support from our esteemedinvestors BeAble Capital, INNVIERTE ECONOMIA SOSTENIBLECOINVERSION SA SCR, and our newest US partner, Dreavent,through their first BIOHORIZONT. By infusing substantial capitalinto our company, A4CELL is poised to enhance the capabilities ofour cutting-edge technologies and strengthen our position at theforefront of the US market.
"We are immensely excited about the possibilities this investmentbrings," remarked Elena Rivas, CEO of A4CELL. "This marks apivotal moment for A4CELL and underscores our dedication topushing the boundaries of single cell analysis, particularly in therealm of understanding and combatting complex diseases suchas cancer”.
The investment will primarily be channeled towards intensifyingresearch and development efforts, expanding our talented teamof researchers and engineers, and accelerating the production ofstate-of-the-art technologies designed to unlock the secretshidden within living single cells.
Through an unwavering commitment to innovation and a steadfastvision for the future, A4CELL is poised to revolutionize the field ofliving single cell analysis and transform scientific research.